Akero Therapeutics Inc [AKRO] stock prices are up 24.72% to $47.57 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AKRO shares have gain 18.90% over the last week, with a monthly amount glided 26.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on January 30, 2025, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $63 from $35. Previously, H.C. Wainwright reaffirmed its Buy rating on January 27, 2025, and elevated its price target to $72. On November 18, 2024, Citigroup initiated with a Buy rating and assigned a price target of $65 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $69 as its price target on September 19, 2023. UBS started tracking with a Buy rating for this stock on August 28, 2023, and assigned it a price target of $83. In a note dated January 27, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $40 to $65.
The stock price of Akero Therapeutics Inc [AKRO] has been fluctuating between $17.86 and $58.40 over the past year. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $47.57 at the most recent close of the market. An investor can expect a potential drop of -3.3% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.32 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Akero Therapeutics Inc [NASDAQ:AKRO]’s Current Ratio is 16.80. Further, the Quick Ratio stands at 16.80, while the Cash Ratio is 4.38.
Transactions by insiders
Recent insider trading involved Yale Catriona, Chief Development Officer, that happened on May 15 ’25 when 10000.0 shares were sold. Officer, CATRIONA YALE completed a deal on May 15 ’25 to buy 30000.0 shares. Meanwhile, President and CEO Cheng Andrew sold 30000.0 shares on May 12 ’25.
